166 related articles for article (PubMed ID: 35773162)
1. Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes.
Ng E; Shaw JE; Wood A; Maple-Brown LJ; Hare MJ
Aust J Gen Pract; 2022 Jul; 51(7):513-518. PubMed ID: 35773162
[TBL] [Abstract][Full Text] [Related]
2. Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
Updike WH; Pane O; Franks R; Saber F; Abdeen F; Balazy DD; Carris NW
Drugs; 2021 Jun; 81(8):881-893. PubMed ID: 33929717
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).
Ghosal S; Datta D; Sinha B
Sci Rep; 2021 Nov; 11(1):22063. PubMed ID: 34764398
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like Peptide 1 Receptor Agonists and Cardiovascular Outcomes in Solid Organ Transplant Recipients With Diabetes Mellitus.
Dotan I; Rudman Y; Turjeman A; Akirov A; Steinmetz T; Calvarysky B; Diker Cohen T
Transplantation; 2024 Jul; 108(7):e121-e128. PubMed ID: 38361246
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
[TBL] [Abstract][Full Text] [Related]
6. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents.
Cornell S
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):17-27. PubMed ID: 32910490
[TBL] [Abstract][Full Text] [Related]
7. Single-center Evaluation of Safety & Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ Transplantation.
Sweiss H; Hall R; Zeilmann D; Escamilla J; Bhayana S; Patel R; Long C
Prog Transplant; 2022 Dec; 32(4):357-362. PubMed ID: 36039519
[No Abstract] [Full Text] [Related]
8. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
Ferreira JP; Saraiva F; Sharma A; Vasques-Nóvoa F; Angélico-Gonçalves A; Leite AR; Borges-Canha M; Carvalho D; Packer M; Zannad F; Leite-Moreira A; Neves JS
Diabetes Obes Metab; 2023 Jun; 25(6):1495-1502. PubMed ID: 36722252
[TBL] [Abstract][Full Text] [Related]
10. Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.
Bzowyckyj A
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):7-16. PubMed ID: 32910488
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
[TBL] [Abstract][Full Text] [Related]
12. Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.
Chang LS; Vaduganathan M; Plutzky J; Aroda VR
Curr Diab Rep; 2019 Dec; 19(12):157. PubMed ID: 31802265
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease.
Gay HC; Yu J; Persell SD; Linder JA; Srivastava A; Isakova T; Huffman MD; Khan SS; Mutharasan RK; Petito LC; Feinstein MJ; Shah SJ; Yancy CW; Kho AN; Ahmad FS
Am J Cardiol; 2023 Feb; 189():121-130. PubMed ID: 36424193
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes.
Al-Ozairi E; Irshad M; Taghadom E; Sojan L; Al Kandari J; Alroudhan D; le Roux CW
Obesity (Silver Spring); 2023 Mar; 31(3):716-723. PubMed ID: 36811241
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
17. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
Shin JI
Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
[TBL] [Abstract][Full Text] [Related]
18. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
[TBL] [Abstract][Full Text] [Related]
19. Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Mannucci E; Monami M
Diabetes Res Clin Pract; 2020 Mar; 161():108087. PubMed ID: 32084455
[TBL] [Abstract][Full Text] [Related]
20. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
